Oguchi disease
Oguchi disease is a rare, autosomal recessive congenital stationary night blindness (CSNB) disorder characterized by a unique golden or grayish discoloration of the retina that reverses after prolonged dark adaptation. This condition is named after the Japanese ophthalmologist Chuta Oguchi, who first described it in 1907.
Clinical Features[edit | edit source]
Patients with Oguchi disease typically present with night blindness (nyctalopia) from an early age. Despite the significant difficulty in seeing in low-light conditions, their daytime vision remains relatively normal. The hallmark of Oguchi disease is the Mizuo-Nakamura phenomenon, where the abnormal golden or grayish discoloration of the retina disappears after several hours of darkness, revealing a normal-appearing retina.
Pathophysiology[edit | edit source]
Oguchi disease is caused by mutations in genes involved in the phototransduction pathway in the retina. The two primary genes associated with this condition are SAG (S-arrestin) and GRK1 (G protein-coupled receptor kinase 1). Mutations in these genes disrupt the normal function of rod photoreceptors, leading to impaired dark adaptation and night blindness.
Diagnosis[edit | edit source]
The diagnosis of Oguchi disease is primarily clinical, based on the characteristic retinal appearance and the Mizuo-Nakamura phenomenon. Electroretinography (ERG) can be used to confirm the diagnosis, showing a typical pattern of reduced rod function with relatively preserved cone function. Genetic testing can identify mutations in the SAG or GRK1 genes, providing a definitive diagnosis.
Treatment[edit | edit source]
There is currently no cure for Oguchi disease. Management focuses on coping strategies for night blindness, such as using bright lighting and avoiding activities in low-light conditions. Genetic counseling may be beneficial for affected individuals and their families.
Epidemiology[edit | edit source]
Oguchi disease is extremely rare, with most cases reported in Japan. However, it has been identified in various populations worldwide. The exact prevalence is unknown due to its rarity and the potential for misdiagnosis as other forms of night blindness.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD